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Abstract:
Introduction:
Tinuvin  770  [bis(2,2,6,6-tetramethyl-4-piperidinyl)  sebacate,  Ciba-Geigy,  Basel,  Switzerland]  is  a  UV  light  stabilizer  that  is  a
component of many plastic materials used world-wide in the medical and food industries. We report on the acute hemodynamic
effects of Tinuvin 770 examined in dogs.
Materials and Methods:
Tinuvin 770 was dissolved in a mixture of saline and ethanol (1:1 v/v) and was administered to 12 intravenously narcotized and
respirated dogs in increasing doses (T1-T7: 1, 3.3, 6.6, 10, 33.3, 66.6 and 100 mg, respectively). The doses were given as bolus
injections over a three minute period, and the effects were recorded for 12 minutes. The vehicle was used as a control. Hemodynamic
parameters (heart rate, blood pressure, end-diastolic pressure, dp/dt, cardiac output) and ECG were monitored continously.
Results:
At doses T1-T4, systolic and diastolic blood pressures,  mean pressure and ventricular contractility were significantly decreased
without  significant  changes  in  cardiac  output,  heart  rate,  or  PQ  interval.  At  doses  T5  and  T6,  declines  in  blood  pressure  and
myocardial  contractility  were  observed.  At  doses  T6  and  T7,  heart  rate  and  PQ  interval  decreased  substantially.  Irreversible
circulatory failure occured in one dog after administering dose T6 and in 8 dogs following dose T7.
Conclusion:
Tinuvin 770 induces acute hemodynamic alterations. In lower doses, it causes peripheral vasodilatation, however at higher doses
acute cardiac failure occured. Plastics containing Tinuvin 770 should be used with care in medical practice and the laboratory.
Keywords:  Tinuvin  770,  L-type  Ca2+  channel,  Nicotinic  acetylcholine  receptor,  Cardiotoxicity,  Circulation,  Hemodynamic
parameters,  dp/dt.
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1. INTRODUCTION
Tinuvin 770 is widely used to stabilise polyethylene [1], polypropylene, polycarbonate, polyurethane, polystyrene,
polyamide, polyacetyl and acrylonitril polymer products [2]. It belongs to the group of sterically Hindered Amine Light
Stabilizers (HALS) [3, 4]. It is preferencially used in stabilizing thin plastic films and membranes used in medicine and
food-industry  [5].  Glossman  and  his  colleagues  reported  that  Tinuvin  770  [bis  (2,2,6,6-tetramethyl-4-piperidinyl)
sebacate,  Ciba-Geigy,  Basel,  Switzerland],  a  UV  stabilizer  [6],  can  be  eluted  from  plastic  laboratory  tubes.  They
showed that the compound is a potent (IC50 values < 10nM) L-type Ca
2+ channel blocker [7]. Tinuvin 770 is structurally
different  from  other  Ca2+  channel  blockers  [8,  9]  it  acts  by  binding  to  the  phenylalkylamine  and  benzothiazepine
selective domain of the α1 subunit  of the L-type Ca2+  channel,  and was shown to decrease the 1,4-dihydropiridine-
sensitive  Ca2+-  uptake  [7].  The  tissue  specificity  of  previously  known  Ca2+  antagonists  is  quite  different.
Dihydropiridines (like Nifedipine) act primarily on the smooth muscle cells of peripheral vessels, inducing dilatation of
the arterioles and coronaries and producing decreased afterload [9]. Dihydropiridines do not affect atrial-ventricular
conduction and slightly decrease myocardial contractility can only be observed following high doses. Their intense
peripheral vasodilatory effect may result in reflex tachycardia [10, 11]. Phenylalkylamines (e.g. Verapamil) act mainly
on the myocardium. Benzothiazepines produce only weak vasodilatory effects and decrease contractility compared to
dihyropiridine. The action of was shown to be similar to that of of benzothiazepines in vitro.
Papke et al. [12] showed that Tinuvin 770, dissolved from plastics used in medical practice, blocks α4, β2 subunit-
containing  nicotinic  acetylcholine  receptors  in  the  central  nervous  system  more  potently  (IC50  ≈200  nM),  than  the
nicotinic ganglion blocker mecamylamine (IC50 ≈10 μM) [13 - 15]. Tinuvin 770 failed to decrease blood pressure and
nociceptive threshold either, and did not alter locomotor activity [15].
We  have  previously  demonstrated  that  in  vitro  Tinuvin-770  has  time-dependent  cardiotoxic  effects  on  isolated
myocardial cells [16] and dose-dependent chronic cardiotoxicity in rats in vivo [17]. It was also shown that Tinuvin 770
increased  intracellular  Ca2+  accumulation  and  catecholamine  release  similarly  to  the  first  generation  L-type  Ca2+
blockers.
In the present study, we aimed to analyze the acute haemodynamic and cardiac effects of Tinuvin 770 in a dog
model.  The  experimental  animal  model  used  is  appropriate  to  study  the  hemodynamic  effects,  to  perform
electrophysiological  monitoring  and  to  determine  the  dose-effect  relationships.
2. MATERIALS AND METHODS
2.1. General Interventions
Acute hemodynamic experiments were performed on 12 mongrel dogs (weight: 24±1 kg, 7 males, 5 female). The
investigation  conformed  to  the  Guide  for  the  Care  and  Use  of  Laboratory  Animals  published  by  the  US  National
Institutes of Health (NIH Publication No. 85-23, revised 1985) and was in accordance with the ethical regulations of
animal care at Semmelweis University. The Regional Ethical Committee of the Semmelweis University approved this
experimental study under No: 42/1999/.
2.2. Particular Intervention
Each animal was initially anaesthetized with intravenous pentobarbital sodium (Nembutal, CEVA, and 30 mg/kg)
and additional  anesthesia was given as needed to maintain an appropriate constant  level  of  narcosis.  After  tracheal
intubations, the dogs were respirated with room air by a Cape CV2424 respirator (Cape Engineering Co. Ltd.). The
right femoral vein was used to administer Tinuvin 770. One of the femoral arteries served for continuous arterial blood
pressure monitoring (Experimetria HG 01 modem, Statham P23Db). The right carotid artery was prepared and a pigtail
catheter was introduced for left ventricular pressure and contractility (dp/dt) measurements (Pigtail Catheter 4F, Cordis
and Experimetria HG 01 modem, Statham P23Db). The left internal jugular vein was used to measure cardiac output
using a wedge pressure balloon catheter, through which 10 ml 10 – 16 °C saline solution was injected at the time of
each  measurement.  A  thermistor  catheter  was  introduced  into  the  aorta  through  the  left  femoral  artery  to  measure
Cardiac  Output  (CO).  Cardiac  output  was  then  calculated  on  the  basis  of  thermodilution.  Measurements  and
calculations  were  performed  with  Experimetria  CO-100,  Cardiostar  equipment.  Standard  surface  ECG  recording
(Madaus Schwarzer CU12) was used to calculate heart rate and measure PQ-intervals.
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A preliminary experiment was carried out to determine the effective dose range of Tinuvin 770. A wide range of
doses (a doses covered six magnitude of concentrations between the lowest  and highest  dose:  1 μg – 100 mg) was
applied. This preliminary experiment was performed on two dogs. These animals were injected by six doses of Tinuvin
770 (1 μg, 10 μg, 100 μg, 1 mg, 10 mg, 100 mg) and by vehicle as control (described in the next section). Tinuvin 770
in doses lower than 1 mg had neither hemodynamic nor electrophysiologic effects; however, none of the dogs survived
the 100 mg dose. Therefore, in the present study the following doses of Tinuvin 770 were used; T1:1mg, T2:3.3mg,
T3:6.6mg, T4:10mg, T5:33.3mg, T6:66.6mg, T7:100 mg.
2.3. Experimental Protocol
After surgical instrumentation, each animal underwent a 20-minute equilibration period. During the next 20-minute
baseline period, haemodynamic parameters and ECG were continuously recorded. Administration of Tinuvin 770 was
started  after  baseline  stabilization  was  achieved.  First,  vehicle  (a  mixture  of  equal  amount  of  saline  solution  and
ethanol) was given intravenously. Then doses T1 – T7 (1; 3,3; 6,6; 10; 33,3; 66,6 és 100 mg of Tinuvin 770 in 5 ml
vehicle) were injected over a 3-minute period. Hemodynamic measurements and ECG monitoring were performed at 0,
3,  6,  9,  12,  and 15 minutes  following Tinuvin 770 injections.  Each dog received all  the 7 doses  of  Tinuvin 770 in
increasing order.
2.4. Statistical Analysis
Data are expressed as means ± SDs. For statistical comparisons repeated measures ANOVA was used. Sphericity
was evaluated using Mauchly’s test. If sphericity was not rejected, a Dunnett test was used for post hoc comparisons of
the first to the other time points. If sphericity could not be supposed, simple contrasts with Bonferroni correction were
evaluated. Values of P<0.05 were considered significant.
3. RESULTS
Following the administration of Tinuvin 770 in doses of T1 – T6, there were statistically significant changes in
every parameter measured. One dog died at 12 minutes after the T6 dose was given because of irreversible circulatory
failure. At dose T7, lethality was 82%: Three dogs died within 3 minutes, and another six died within 6 minutes. Only
two animals survived this dose.
3.1. Systolic Arterial Pressure
There were no statistically significant blood pressure changes at the T1. At the T2 dose a small effect on blood
pressure was measured at 3 minutes (T2: ∆%≈ -0,058) that ended at 6 minutes. After doses of T3 and T4, an effect on
blood presure was seen at 3 minutes with maximum at 6 minutes (T3: ∆%≈ -0.064, T4: ∆%≈ -0.108) that disappeared
by 9 minutes. After doses of T5 and T6 blood pressure decreased at 3 minutes, reached a nadir at 6 minutes (T5: ∆%≈
-0,302, T6: ∆%≈ -0,460) and remained low afterwards. By 15 minutes, systolic pressure had nearly returned to normal
value (T5: ∆%≈ -0,143 T6: ∆%≈ -0,265) (Fig. 1).
3.2. Diastolic Arterial Pressure
There were no statistically significant changes in diastolic blood pressure after the T1dose. Following doses of T2
and T3 there were small decreases in diastolic pressure at the 6-minute timepoint (T2: ∆%≈ -0.067, T3: ∆%≈ -0.052).
The T4 dose caused a decrease in diastolic pressure at 3 and 6 minutes (T4: ∆%≈ -0.118). Doses of T5 and T6 caused
decreases in diastolic pressure that began at 3 minutes, peaked at 6 minutes (T5: ∆%≈ -0.319, T6: ∆%≈ -0.463) and
gradually wore off afterwards (T5: ∆%≈ -0.163, T6: ∆%≈ -0.272) (Fig. 2).
3.3. Mean Blood Pressure
Neither  the vehicle  nor  the T1 dose had an effect  on mean blood pressure.  The T2 dose decreased mean blood
pressure after 6 minutes (T2: ∆%≈ -0.0601); the effect disappeared within 3 minutes. Doses of T3 and T4 (T3: ∆%≈
-0.071,  T4:  ∆%≈  -0.111)  caused  a  blood  pressure  decrease  within  3  minutes,  that  further  decreased  by  6  minutes
however the effect disappeared by 9 minutes. Doses of T5 and T6 decreased mean blood pressure within 3 minutes.
This  effect  peaked  at  6  minutes  (T5:  ∆%≈ -0.298,  T6:  ∆%≈ -0.467)  and  persisted  until  the  end  of  the  15  minutes
observation period.
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Fig. (1). Effects of Tinuvin 770 on systemic systolic blood pressure (Hgmm). Statistical significance is marked with * (P<0.05).
Fig. (2). Effects of Tinuvin 770 on systemic diastolic blood pressure (Hgmm). Statistical significance is marked with * (P<0.05).
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3.4. Positive dp/dt Values
Administration of the vehicle and theT1 dose had no effect on positive dp/dt values. The T2 dose had a maximum
effect at 3 minutes (T2: ∆%≈ -0.094), which persisted by the 6 minute timepoint,  at 9 minutes no differences were
observed. The T3 dose also had a maximum effect at 3 minutes (T3: ∆%≈ -0.101), that ended within 12 minutes. At
doses of T4, T5 and T6 the effects on positive dp/dt began at 3 minutes, reached a maximum at 6 minutes (T4: ∆%≈
-0.123, T5: ∆%≈ -0.238, T6: ∆%≈ -0.486) and lasted until the end of the experiment. By 15 minutes, values had nearly
returned to initial values (T4: ∆%≈ -0.066, T5: ∆%≈ -0.155, T6: ∆%≈ -0.263) (Fig. 3).
Fig. (3). Effects of Tinuvin 770 on positive dp/dt (Hgmm/sec). Statistical significance is marked with * (P<0.05).
3.5. Negative dp/dt Values
There were no changes following administration of vehicle and the T1 dose. The T2 dose elicited a decrease in
negative dp/dt (∆%≈ -0.082) that disappeared by 9 minutes. The maximal effect of the dose of T3 appeared at 3 minutes
(T3: ∆%≈ -0.093) and ended by 9 minutes. At doses T4, T5, and T6 changes were seen from 3 minutes until the end of
the experiment (T4: ∆%≈ -0.088, T5: ∆%≈ -0.117, T6: ∆%≈ -0.475). At 15 minutes values had almost returned to the 0
time point levels (T4: ∆%≈ -0.060, T5: ∆%≈ -0.113, T6: ∆%≈ -0.309). Since the negative dp/dt is equal to the positive
dp/dt proportion, only the positive values are presented in Fig. (3).
3.6. Heart Rate
Vehicle and dose T1 had no effect on heart rate. Dose T5 decreased heart rate at timepoints 12 and 15. (T5: ∆%≈
0.039). Dose T6 decreased the rate by minute 9, and this effect persisted until 15 minutes (T6: ∆%≈ 0.108) (Table 1).
3.7. Atrio-Ventricular Conduction
We characterized atrio-ventricular conduction by measuring the PQ interval. Vehicle and the T1-T3 doses had no
effect on the PQ interval. Following T4 dose PQ interval decreased at 12 minutes (T4: ∆%≈ 1.025). The PQ decreasing
effect of the Tinuvin 770 T5 and T6 doses began at 3 minutes. At dose T5 the PQ decrease reached a minimal at 12
minutes (T5: ∆%≈ 1.084), and the dose of T6 reached a minimal at 9 minutes. Following the T5 and T6 doses, the
change in the PQ interval returned almost to the initial value at 15 minutes (T5: ∆%≈ 1.059, T6: ∆%≈ 1.088) (Table 2).
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Table 1. Heart rate in relation to time following administration of different doses of Tinuvin 770. T1-T7 symbols represent 1,
3.3, 6.6, 10, 33.3, 66.6, and 100 mg of Tinuvin 770, respectively. Statistically significant differences are marked with bold
numbers and * (P<0.05).
Time (minutes) Vehicle T1 dose T2 dose T3 dose T4 dose T5 dose T6 dose
0 160,6 ±6,5 155,9 ±5,8 162,8 ±4,6 162,8 ±4,9 156,3 ±6,3 153,7 ±5,6 147 ±6,5
3 158 ±5,3 155,2 ±5,3 163,2 ±4,4 165,7 ±4,9 157,5 ±6,7 159 ±8,0 148 ±8,8
6 158,4 ±5,8 154,1 ±5,4 163,1 ±4,3 165,3 ±5,1 156,5 ±6,3 156,4 ±8,2 142,9 ±8,8
9 158,1 ±6,3 156,4 ±5,6 163,7 ±4,8 164,2 ±5,0 154,5 ±6,1 151,4 ±7,5 136 ±7,9*
12 157,5 ±6,3 156,9 ±5,7 163,3 ±4,6 163,5 ±5,7 152,9 ±6,2 148 ±6,7* 135 ±8,4*
15 156,7 ±6,0 156,5 ±5,4 163,6 ±4,8 162,7 ±6,1 151,2 ±6,3 147 ±6,6* 131 ±9,6*
Table 2. Atrio-ventricular conduction. Extension of PQ interval in relation to time following different doses of Tinuvin 770 in
dogs T1-T7 symbols represent 1,  3.3,  6.6,  10, 33.3, 66.6,  and 100 mg of Tinuvin 770, respectively. Statistically significant
differences are marked with bold numbers and * (P<0.05).
Time (minutes) Vehicle T1 dose T2 dose T3 dose T4 dose T5 dose T6 dose
0 0,114±,003 0,118±,003 0,114±,003 0,117±,004 0,120±,003 0,118±,004 0,124±,004
3 0,113±,003 0,120±,004 0,117±,004 0,119±,005 0,120±,004 0,125±,004* 0,129±,006*
6 0,114±,003 0,123±,003* 0,119±,003 0,120±,004 0,122±,004 0,125±,004* 0,135±,006*
9 0,114±,003 0,122±,004 0,120±,004 0,119±,004 0,122±,004 0,126±,005* 0,136±,007*
12 0,114±,003 0,119±,003 0,119±,004 0,119±,004 0,123±,004* 0,128±,004* 0,135±,007*
15 0,114±,003 0,118±,003 0,117±,004 0,117±,004 0,122±,004 0,125±,004* 0,135±,008*
3.8. End-Diastolic Left Ventricular Pressure
There was no change in the End-Diastolic left ventricular Pressure (EDP) at doses T1 and T2. The mean pressure
values were around 7 mmHg. However following T3 and T4doses, the EDP values increased to more than 10 mmHg
(T3: ∆%≈ 1.264, T4: ∆%≈ 1.385) and no further increase was observed at doses of T5 and T6. The effect of dose T7
could not be estimated.
3.9. Cardiac Output
There were no statistically significant changes in Cardiac Output (CO) up to dose of T6. Animals that died soon
after the administration of the T7 dose showed a significant decrease in cardiac output. The 3 minute values (T7: ∆%≈
0.244)  could  only  be  collected  from  9  dogs,  since  three  dogs  died  soon  after  the  T7  dose  of  Tinuvin  770  was
administered. By 6 minutes, six more dogs were lost, so there were not enough survivors for statistical analysis.
3.10. Systemic Vascular Resistance (SVR)
SVR  was  calculated  from  Mean  Arterial  Pressure  (MAP)  and  Cardiac  Output  (CO).  SVR=MAP/CO
(HgmmXmin/l). There were no statistically significant changes following doses of T1, T2 or T3. At dose T4 a decrease
of  SVR was  observed after  3  minutes  (T4:  ∆%≈ -0.11);  that  lasted  till  9  minutes.  After  the  doses  of  T5 and T6,  a
maximal decrease in SVR was seen at 3 minutes; (T5: ∆%≈ -0.44, T6: ∆%≈ -0.49) this effect slowly regressed by 6
minutes (T5: ∆%≈ -0.23, T6: ∆%≈ -0.33) and the SVR value nearly returned to initial normal value by the 15 minute
timepoint (T6: ∆%≈ -0.25) (Fig. 4).
Circulatory  failure  was  predicted  by  ischemic  changes  on  the  ECG record  (negative  T  wave,  ST depression  or
elevation), by ventricular extra systoles, and also by ventricular fibrillation.
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Fig. (4). Effects of Tinuvin 770 on systemic vascular resistance ([HgmmXmin]/l). Statistical significance is marked with * (P<0.05).
4. DISCUSSION
The  dose  range  determined  in  our  preliminary  experiment  seemed  to  be  appropriate  to  characterize  the  acute
hemodynamic  and  cardiac  effects  of  Tinuvin  770.  We  did  not  detect  statistically  significant  hemodynamic  or
electrophysiological effects of the compound at the lowest dose (1mg) studied. In contrast, 75% of the dogs suffered
irreversible  circulatory  failure  and  died  following  the  administration  of  the  highest  Tinuvin  770  dose  (100  mg).
Hemodynamic effects of Tinuvin 770 were shown dose-dependent. Tinuvin 770 caused changes in hemodynamic and
ECG  parameters  resembles  that  of  typical  Ca2+  antagonist  compounds,  although  not  identical  [10,  11].
Dihydropyridines,  (for  example  Nifedipin)  due to  their  vascular  selectivity,  mainly  initiate  vasodilatation and their
impact  on  the  heart  is  substantially  weaker.  Phenylalkylamines  (like  Verapamil)  are  considered  cardioselective
effectively  decreasing  PQ,  decreasing  heart  rate,  and  causing  a  negative  chronotropic  effect.  The  actions  of  the
benzothiazepines (like Diltiazem) are also localized mainly on the heart, although their cardioselectivity does not reach
that of phenylalkylamines. Chronic cardiotoxicity caused by Tinuvin 770 was also shown in our previous in vitro and in
vivo studies [16, 18]. In our present study, there were dose-dependent decreases both in systolic and diastolic blood
pressure values beginning from the dose of T2, and dose T6 caused a 46 percent fall in blood pressure. At dose T7
blood pressure dropped to zero in 9 of the 12 dogs when their heart failed. While changes in myocardial contractility
paralleled those in blood pressure at lower doses, an unequivocal drop in contractility was seen at dose T5 (33.3 mg),
and  this  became  quite  pronounced  (-40%)  following  dose  T6  (66.6  mg).  Negative  and  positive  dp/dt  values  were
observed. The decrease of positive dp/dt up to the T5 dose exceeded the decrease of the negative dp/dt. This difference
was most pronounced at dose T5, where the positive dp/dt denoted a twice as high downfall than the negative one. At
dose T6 (66.6 mg) the drop for both parameters were nearly the same. At dose T7 contractility was immeasurable.
Higher T3 and T4 doses (6,6; 10 mg) elicited an end diastolic left ventricular pressure increase of 10 Hgmm that did not
increase further at higher doses (T5 and T6). A statistically significant acute decrease in heart rate was only seen at
doses of T5 and of T6 (33.3 and 66.6 mg). The decline reached 10 percent at the dose T6. A decrease in PQ interval
(not exceeding 10%) could also only be detected at doses of T5 and T6 (33.3 and 66.6 mg). Tinuvin 770 at doses of T1-
T6  (1-66.6  mg)  did  not  influence  cardiac  output.  However,  the  T7  dose  (100  mg)  resulted  in  circulatory  failure
associated to a marked fall in CO. Only three of 12 dogs were able to compensate the 100 mg dose of Tinuvin 770 and
their  circulatory  parameters  returned  to  baseline  values  only  after  long  period  (60min)  of  time.  The  ECG  records
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showed also signs of severe ischemia. Since cardiac output was found constant, the values of SVR reflect changes in
mean arterial pressure at doses of T1-T5. SVR declined in parallel with CO.
Tinuvin 770 dissolved from plastic containers can be absorbed in the human body [19]. It may enter the circulation
following  oral  administration,  or  can  be  absorbed  through  the  skin,  mucosal  membranes,  or  can  directly  reach
circulation  via  bandages,  catheters,  cannulas,  etc.
Haemodialysis treatment seems to have the danger. Tinuvin 770 contamination of the body can be facilitated by the
1-1.8 square meter surface area of the dialysis membrane, the 250-300 ml/min rate of blood flow, and the repeated
treatments [20]. It is worth mentioning, however, that few of the complications associated with hemodialysis treatments
have unequivocally been correlated with the dialysis membranes.  Reported hemodyalisis associated adverse effects
include intoxication caused by chemicals used for sterilization [21, 22], pyrogenic reactions [23], membrane-medication
interactions [24], and some specific reactions that developed when certain specific membranes were used [25 - 27].
Among acute hemodyalisis complications, hypotension, that develops during or immediately after dialysis treatment,
has 15-20 percent prevalence [28]. Clinical symptoms (vomiting, dizziness, loss of consciousness) appear together with
a  drop  of  blood  pressure  by  30-50  Hgmm.  Concomitant  factors  are  decreased  blood  volume,  reduced  peripheral
vasoconstriction and cardiac factors (known ischemic heart disease, arrhythmia, diminished left ventricular function)
[29, 30].
Tinuvin 770 is present in different dialysis membranes is extracted by aqueous phase plasma-like solutions [18],
was  shown  to  act  as  an  L-type  Ca2+  channel  blocker.  It  could  contribute  to  the  development  of  dialysis-related
hypotension through its cardiovascular and central nervous system effects.
Our  present  in  vivo  results  summarized  above  support  our  earlier  in  vitro  observations  that  Tinuvin  770  is  an
effective L-type Ca2+ channel inhibitor. However, its mode of action seems to be complex being closest to that of the
benzothiazepines  (e.g.  Diltiazem),  vs  Phenylalkylamines  (e.g.  Verapamil)  or  dihydropiridines  (e.g.  Nifedipin).  Its
actions are not identical to those of any clinically used L-type Ca2+ channel blocker. At lower doses (3.3 – 10 mg), it
primarily  has  peripheral  effects.  Mild vasodilatation helps  the pumping function of  the heart,  decreasing after-load
accelerates  motion  of  the  left  ventricle,  and  it  decreases  tension  of  the  ventricular  wall  and  improves  coronary
circulation. These effects are supported by the data presented, namely that the initially increasing EDP is not rising any
further. However, at higher doses, its acute cardiac effects become more marked. A gradual decrease in ventricular
contractility lead to cardiovascular failure – as observed following the administration of the extra high doses of T6
andT7 (66.6 and 100 mg) of  Tinuvin 770.  Atrio-ventricular  conduction was only influenced significantly at  higher
doses,  but  without  clinically  significant  alterations  in  the  heart  rate.  Besides  its  negative  inotropic  and  peripheral
vasodilatative effects, at high subtoxic doses, an acute negative chronotropic effect can also contribute to its complex
effect due to the increased atrio-ventricular conduction time observed. On the basis of the dose range tested, EC50 (EC50
≤ 0137 mg/body weight) and LD50 (LD50 ≤ 4 mg/ body weight) were calculated. Based on the data presented, further
studies are needed to clarify the exact mode of action of Tinuvin 770 on cardiac function.
CONCLUSION
Our   present   results   show   that  the   L-type   Ca2+  channel   inhibitory  effect   of  Tinuvin   770   suggested  by
 Glossmann   et  al.  [7]  could  be  demonstrated  in  an  in  vivo  experimental  setting  examining  acute  hemodynamic
parameters in dogs. We also showed that Tinuvin 770 causes acute cardiac failure at  higher doses administered. In
further studies, we plan to determine those factors that facilitate dissolution of Tinuvin 770 in cardioactive amounts
from dialysis membranes and other medical plastics that may produce acute hemodynamic alterations in patients.
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